An antibody that blocks human T-cell leukemia virus type 1 six-helix-bundle formation in vitro identified by a novel assay for inhibitors of envelope function

Journal of General Virology

Volumn 88, Issue 2, 2007, Pages 660-669

  Mirsaliotis, Antonis ^a   Nurkiyanova, Kulpash ^a   Lamb, Daniel ^a   Kuo, Chien Wen S ^a   Brighty, David W ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOGENICITY; IN VITRO STUDY; MEMBRANE FUSION; MOLECULAR MIMICRY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CELL MEMBRANE; GLYCOPROTEINS; HELA CELLS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MEMBRANE FUSION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN CONFORMATION; VIRAL ENVELOPE PROTEINS;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33846786782     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.82390-0     Document Type: Article

References (53)

1. Baba, M., Yuasa, S., Niwa, T., Yamamoto, M., Yabuuchi, S., Takashima, H., Ubasawa, M., Tanaka, H., Miyasaka, T. & other authors (1993). Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochem Pharmacol 45, 2507-2512.
2. Baker, K. A., Dutch, R. E., Lamb, R. A. & Jardetzky, T. S. (1999). Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 3, 309-319.
3. Blanchard, S., Astier-Gin, T., Tallet, B., Moynet, D., Londos-Gagliardi, D. & Guillemain, B. (1999). Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies. J Virol 73, 9369-9376.
4. Brighty, D. W. & Jassal, S. R. (2001). The synthetic peptide P-197 inhibits human T-cell leukemia virus type 1 envelope-mediated syncytium formation by a mechanism that is independent of Hsc70. J Virol 75, 10472-10478.
5. Bullough, P. A., Hughson, F. M., Skehel, J. J. & Wiley, D. C. (1994). Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371, 37-43.
6. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A. & Wyatt, R. T. (2004). HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5, 233-236.
7. Burton, D. R., Stanfield, R. L. & Wilson, I. A. (2005). Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102, 14943-14948.
8. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273.
9. Deen, K. C., McDougal, J. S., Inacker, R., Folena-Wasserman, G., Arthos, J., Rosenberg, J., Maddon, P. J., Axel, R. & Sweet, R. W. (1988). A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 331, 82-84.
10. Delamarre, L., Pique, C., Pham, D., Tursz, T. & Dokhelar, M. C. (1994). Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein. J Virol 68, 3544-3549.
11. Delamarre, L., Rosenberg, A. R., Pique, C., Pham, D. & Dokhelar, M. C. (1997). A novel human T-leukemia virus type 1 cell-to-cell transmission assay permits definition of SU glycoprotein amino acids important for infectivity. J Virol 71, 259-266.
12. Delamarre, L., Pique, C., Rosenberg, A. R., Blot, V., Grange, M. P., Le Blanc, I. & Dokhelar, M. C. (1999). The Y-S-L-I tyrosine-based motif in the cytoplasmic domain of the human T-cell leukemia virus type 1 envelope is essential for cell-to-cell transmission. J Virol 73, 9659-9663.
13. de Rosny, E., Vassell, R., Jiang, S., Kunert, K. & Weiss, C. D. (2004). Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp4l: implications for fusion-inducing conformational changes. J Virol 78, 2627-2631.
14. Desgranges, C., Souche, S., Vernant, J. C., Smadia, D., Vahlne, A. & Horal, P. (1994). Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera. AIDS Res Hum Retroviruses 10, 163-173.
15. Dokhelar, M. C., Pickford, H., Sodroski, J. & Haseltine, W. A. (1989). HTLV-1 p27rex regulates gag and env protein expression. J Acquir Immune Defic Syndr 2, 431-440.
16. Eckert, D. M. & Kim, P. S. (2001). Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70, 777-810.
17. Fass, D., Harrison, S. C. & Kim, P. S. (1996). Retrovirus envelope domain at 1.7 Å resolution. Nat Struct Biol 3, 465-469.
18. Fisher, R. A., Bertonis, J. M., Meier, W., Johnson, V. A., Costopoulos, D. S., Liu, T., Tizard, R., Walker, B. D., Hirsch, M. S. & other authors (1988). HIV infection is blocked in vitro by recombinant soluble CD4. Nature 331, 76-78.
19. Golding, H., Zaitseva, M., de Rosny, E., King, L. R., Manischewitz, J., Sidorov, L, Gorny, M. K., Zolia-Pazner, S., Dimitrov, D. S. & Weiss, C. D. (2002). Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 76, 6780-6790.
20. Jassal, S. R., Lairmore, M. D., Leigh-Brown, A. J. & Brighty, D. W. (2001). Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells. Virus Res 78, 17-34.
21. Jiang, S., Lin, K., Strick, N. & Neurath, A. R. (1993). HIV-1 inhibition by a peptide. Nature 365, 113.
22. Jinno, A., Haraguchi, Y., Shiraki, H. & Hoshino, H. (1999). Inhibition of cell-free human T-cell leukaemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein. J Virol 73, 9683-9689.
23. Johnston, E. R. & Radke, K. (2000). The SU and TM envelope protein subunits of bovine leukemia virus are linked by disulfide bonds, both in cells and in virions. J Virol 74, 2930-2935.
24. Kilby, J. M. & Eron, J. J. (2003). Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348, 2228-2238.
25. Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D. & other authors (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4, 1302-1307.
26. Kobe, B., Center, R. J., Kemp, B. E. & Poumbourios, P. (1999). Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci U S A 96, 4319-4324.
27. Kuroki, M., Nakamura, M., Itoyama, Y., Tanaka, Y., Shiraki, H., Baba, E., Esaki, T., Tatsumoto, T., Nagafuchi, S. & Nakano, S. (1992). Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1. J Immunol 149, 940-948.
28. Lalezari, J. P., Henry, K, O'Hearn, M., Montaner, J. S., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R. & other authors (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348, 2175-2185.
29. Liu, S., Lu, H., Niu, J., Xu, Y., Wu, S. & Jiang, S. (2005). Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280, 11259-11273.
30. Louis, J. M., Nesheiwat, I., Chang, L., Clore, G. M. & Bewley, C. A. (2003). Covalent trimers of the internal N-terminal trimeric: coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278, 20278-20285.
31. Lu, M. & Kim, P. S. (1997). A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 15, 465-471.
32. Lu, M., Blacklow, S. C. & Kim, P. S. (1995). A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2, 1075-1082.
33. Malashkevich, V. N., Chan, D. C., Chutkowski, C. T. & Kim, P. S. (1998). Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad activity of gp41 peptides. Proc Natl Acad Sci U S A 95, 9134-9139.
34. Malashkevich, V. N., Scheider, B. J., McNally, M. L., Milhollen, M. A., Pang, J. X. & Kim, P. S. (1999). Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci U S A 96, 2662-2667.
35. Miller, M. D., Geleziunas, R., Bianchi, E., Lennard, S., Hrin, R., Zhang, H., Lu, M., An, Z., Ingallinella, P. & other authors (2005). A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102, 14759-14764.
36. Moulard, M., Lortat-Jacob, H., Mondor, I., Roca, G., Wyatt, R., Sodroski, J., Zhao, L., Olson, W., Kwong, P. D. & Saftentau, O.,J. (2000). Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74, 1948-1960.
37. Palker, T. J., Riggs, E. R., Spragion, D. E., Muir, A. J., Scearce, R. M., Randall, R. R., McAdams, M. W., McKnight, A., Clapham, P. R. & other authors (1992). Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol 66, 5879-5889.
38. Piñon, J. D., Klasse, P. J., Jassal, S. R., Welson, S., Weber, J., Brighty, D. W. & Sattentau, Q J. (2003a). Human T-cell leukemia virus type I envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 77, 9922-9930.
39. Piñón, J. D., Kelly, S. M., Price, N. C., Flanagan, J. U. & Brighty, D. W. (2003b). An antiviral peptide targets a coiled-cod domain of the human T-cell leukemia virus envelope glycoprotein. J Virol 77, 3281-3290.
40. Pique, C., Tursz, T. & Dokhelar, M. C. (1990). Mutations introduced along the HTLV-I envelope gene result in a non-functional protein: a basis for envelope conservation? EMBO J 9, 4243-4248.
41. Pique, C., Pham, D., Tursz, T. & Dokhelar, M. C. (1992). Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation. J Virol 66, 906-913.
42. Pique, C., Pham, D., Tursz, T. & Dokhelar, M. C. (1993). The cytoplasmic domain of the human T-cell leukemia virus type I envelope can modulate envelope functions in a cell type-dependent manner. J Virol 67, 557-561.
43. Poon, B. & Chen, I. S. (1998). Identification of a domain within the human T-cell leukemia virus type 2 envelope required for syncytium induction and replication. J Virol 72, 1959-1966.
44. Rosenberg, A. R., Delamarre, L., Pique, C., Pham, D. & Dokhelar, M.-C. (1997). The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events. J Virol 71, 7180-7186.
45. Rosenthal, P. B., Zhang, X., Formanowski, F., Fitz, W., Wong, C. H., Meier-Ewert, H., Skehel, J. J. & Wiley, D. C. (1998). Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Nature 396, 92-96.
46. Sagara, Y., Inoue, Y., Shiraki, H., Jinno, A., Hoshino, H. & Maeda, Y. (1996). Identification and mapping of functional domains on human T-cell lymphotropic virus type I envelope proteins by using synthetic peptides. J Virol 70, 1564-1569.
47. Shida, H., Tochikura, T., Sato, T., Konno, T., Hirayoshi, K, Seki, M., Ito, Y., Hatanaka, M., Hinuma, Y. & other authors (1987). Effect of the recombinant vaccinia viruses that express HTLV-1 envelope gene on HTLV-1 infection. EMBO 16, 3379-3384.
48. Sodroski, J. G. (1999). HIV-1 entry inhibitors in the side pocket. Cell 99, 243-246.
49. Tanaka, Y., Zeng, L., Shiraki, H., Shida, H. & Tozawa, H. (1991). Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol 147, 354-360.
50. Wallin, M., Ekstrom, M. & Garoff, H. (2004). Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion. EMBO J 23, 54-65.
51. Weissenhorn, W., Carfi, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. (1998). Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 2, 605-616.
52. Wild, C., Oas, T., McDanal, C., Bolognesi, D. & Matthews, T. (1992). A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89, 10537-10541.
53. Wilson, I. A., Skehel, J. J. & Wiley, D. C. (1981). Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289, 366-373.